Rossi G P, Andreis P G, Neri G, Tortorella C, Pelizzo M R, Sacchetto A, Nussdorfer G G
Department of Clinical and Experimental Medicine, School of Medicine, University of Padua, Italy.
J Investig Med. 2000 Sep;48(5):343-50.
The mechanisms and factors leading to enhanced aldosterone secretion and ultimately to neoplastic transformation of the adrenal cortex are poorly defined. Angiotensin-II (Ang-II) and endothelin-1 (ET-1) have emerged as likely candidates among potential aldosterone secretagogues and adrenocortical growth-promoting factors. We therefore compared the effects of Ang-II and ET-1 on steroid hormone secretion of Conn's adenomas.
Ten Conn's adenomas that showed responsiveness to Ang-II blockade in vivo were recruited. Fragments of the tumors were collected immediately after surgical excision, and dispersed cells were obtained by collagenase digestion and mechanical disaggregation. Steroid hormones secreted by dispersed Conn's adenoma cells were assayed by quantitative high-performance liquid chromatography or radioimmunoassay.
Both Ang-II and ET-1 (10(-9) mol/L) similarly enhanced the overall steroid hormone production. ET-1 raised the release of pregnenolone (as evaluated by blocking its further metabolism by cyanoketone), corticosterone, 18-hydroxycorticosterone, and aldosterone, without affecting that of 11-deoxycortisol, cortisol, and 11-deoxycorticosterone. The hormonal responses to ET-1 were partially reversed by 10(-7) mol/L of either the ETA-receptor antagonist BQ-123 or the ETB-receptor antagonist BQ-788 and were abolished when both antagonists were used together. The aldosterone response to the selective activation of ETA and ETB receptors was studied in three Conn's adenomas by exposing dispersed cells to ET-1 (10(-9) mol/L) plus BQ-788 (10(-7) mol/L) and to the ETB-receptor agonist BQ-3020 (10(-8) mol/L). Both treatments raised aldosterone output by about 2-fold. ETA receptor-mediated aldosterone response was abolished by the protein kinase (PK) C inhibitor calphostin C (10(-5) mol/L). ETB receptor-mediated secretory response was lowered by either calphostin C and the cyclooxygenase (COX) inhibitor indomethacin (10(-5) or 10(-4) mol/L) and was completely suppressed when these two were combined. The PKA inhibitor H-89 and the lipoxygenase inhibitor phenidone were ineffective.
Collectively, our findings indicate that Ang-II and ET-1 equipotently stimulate both early and late steps of aldosterone synthesis in Conn's adenoma cells. The secretagogue effect of ET-1 occurs via the activation of ETA and ETB receptors, which are coupled with the PKC-dependent and the PKC- and COX-dependent signaling pathways, respectively.
导致醛固酮分泌增加并最终引起肾上腺皮质肿瘤转化的机制和因素目前尚不清楚。血管紧张素-II(Ang-II)和内皮素-1(ET-1)已成为潜在的醛固酮分泌刺激剂和肾上腺皮质生长促进因子中的可能候选者。因此,我们比较了Ang-II和ET-1对Conn腺瘤类固醇激素分泌的影响。
招募了10例在体内对Ang-II阻断有反应的Conn腺瘤。手术切除后立即收集肿瘤组织碎片,通过胶原酶消化和机械分散获得分散细胞。通过定量高效液相色谱法或放射免疫分析法测定分散的Conn腺瘤细胞分泌的类固醇激素。
Ang-II和ET-1(10⁻⁹ mol/L)同样增强了总的类固醇激素生成。ET-1增加了孕烯醇酮(通过氰酮阻断其进一步代谢来评估)、皮质酮、18-羟皮质酮和醛固酮的释放,而不影响11-脱氧皮质醇、皮质醇和11-脱氧皮质酮的释放。10⁻⁷ mol/L的ETA受体拮抗剂BQ-123或ETB受体拮抗剂BQ-788可部分逆转ET-1引起的激素反应,当两种拮抗剂一起使用时反应被消除。通过将分散细胞暴露于ET-1(10⁻⁹ mol/L)加BQ-788(10⁻⁷ mol/L)以及ETB受体激动剂BQ-3020(10⁻⁸ mol/L),研究了三种Conn腺瘤中ETA和ETB受体选择性激活对醛固酮的反应。两种处理均使醛固酮产量提高约2倍。蛋白激酶(PK)C抑制剂钙泊三醇(10⁻⁵ mol/L)可消除ETA受体介导的醛固酮反应。钙泊三醇和环氧合酶(COX)抑制剂吲哚美辛(10⁻⁵或10⁻⁴ mol/L)均可降低ETB受体介导的分泌反应,当两者联合使用时反应被完全抑制。PKA抑制剂H-89和脂氧合酶抑制剂非那吡啶无效。
总体而言,我们的研究结果表明,Ang-II和ET-1在刺激Conn腺瘤细胞醛固酮合成的早期和晚期步骤方面具有同等效力。ET-1的促分泌作用是通过激活ETA和ETB受体而发生的,它们分别与PKC依赖性和PKC及COX依赖性信号通路偶联。